Hypercalcemia of malignancy remains a clinically relevant problem.
Van Poznak
Catherine
C
University of Michigan Comprehensive Cancer Center, Breast Oncology program, Ann Arbor, Michigan 48109-0942, USA. cvanpozn@umich.edu
D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D005708:Gallium / Q000627:therapeutic use; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy* / Q000209:etiology; D007093:Imidazoles / Q000627:therapeutic use; D009369:Neoplasms / Q000150:complications*; D000077268:Pamidronate; D010257:Paraneoplastic Syndromes / Q000188:drug therapy* / Q000209:etiology; D000077211:Zoledronic Acid
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D005708:Gallium; D000077268:Pamidronate; C027235:gallium nitrate